Corcept Therapeutics

Corcept Therapeutics, based in Redwood City, California, and listed as CORT, is a cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026. Relacorilant, sold as Lifyorli, is a cortisol modulator used in platinum-resistant ovarian cancer on the ROSELLA trial and in Cushing's syndrome. OnCo links it to ovarian cancer and adrenocortical carcinoma, to the ROSELLA trial record and to the relacorilant drug record. Whether blocking cortisol signalling helps chemotherapy in tumours beyond ovarian cancer is the open question its approval raises. Relacorilant has its own page.